Interim report July-September 2017
Vicore Pharma Holding publish the interim report for the third quarter, 2017.Important events during the third quarter 2017 · In August, the initial analysis of the results of the Phase I extension study was presented. The results verified that C21 is well tolerated and safe in a group with a potentially compromised metabolic situation. In addition, the study indicated positive effects on lipid metabolism. Important events after the period · In October, data from the in-depth analysis of the Phase I extension study was presented. The analysis strengthens previously published